Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
PDAC - Pancreatic Ductal Adenocarcinoma: early-phase trial registry
9 of 11 indexed PDAC - Pancreatic Ductal Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 9 currently recruiting · #1,577 of 28,707 conditions by registered trial count
PDAC - Pancreatic Ductal Adenocarcinoma: 11 US clinical trials tracked, 9 recruiting.
PDAC - Pancreatic Ductal Adenocarcinoma is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Revolution Medicines, running 2 of these trials.
Enrollment posture brief
Registry condition pdac-pancreatic-ductal-adenocarcinoma
OPEN 9 | RECR 82% | LATE 2 | EARLY 7 | RANK #1577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Gynecologic Cancers (82% recruiting · 11 trials)
PDAC - Pancreatic Ductal Adenocarcinoma lists 9 open slots (82% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for PDAC - Pancreatic Ductal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
PDAC - Pancreatic Ductal Adenocarcinoma is recruiting above its size-band peers.
9 of 11 indexed trials (81.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates PDAC - Pancreatic Ductal Adenocarcinoma research.
Revolution Medicines accounts for 2 of 11 trials (18.2%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical PDAC - Pancreatic Ductal Adenocarcinoma enrolment sits around 387 participants.
Median target enrolment is 387 among the 11 trials that report a genuine target (sentinel values excluded). 0 of those (0%) plan for fewer than 100 participants.
-
PDAC - Pancreatic Ductal Adenocarcinoma research is mostly interventional.
9 interventional and 2 observational studies make up this index (81.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Dana-Farber Cancer Institute
NCT06122896
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
Mayo Clinic
NCT06151223
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines
NCT07252232
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT06917079
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
NCT04900818
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics
NCT06835569
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Tango Therapeutics
NCT06922591
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Avacta Life Sciences
NCT07454642
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
Engeneic Pty Limited
NCT07049055
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines
NCT06625320
Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer
Immunovia
NCT06947382
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on PDAC - Pancreatic Ductal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on PDAC - Pancreatic Ductal Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this PDAC - Pancreatic Ductal Adenocarcinoma page
11 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 PDAC - Pancreatic Ductal Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Revolution Medicines sponsors the most PDAC - Pancreatic Ductal Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Revolution Medicines's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This PDAC - Pancreatic Ductal Adenocarcinoma condition card totals 11 registered trials; most-linked intervention RMC-6236; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.